Work

Management of Acute Stroke in Patients Taking Novel Oral Anticoagulants

Year: 2014

Type: review

Abstract: Each year, 1·0-2·0% of individuals with atrial fibrillation and 0·1-0·2% of those with venous thromboembolism who are receiving one of the novel oral anticoagulants (dabigatran, rivaroxaban, or apixaban) can be expected to experience an acute ischemic stroke. Additionally, 0·2-0·5% of individuals with atrial fibrillation who are receiving one of the novel oral anticoagulants can be expected to experience an intracranial hemorrhage. This opinion piece addresses the current literature and offers practical approaches to the management of patients receiving novel oral anticoagulants who present with an ischemic or hemorrhagic stroke. Specifically, we discuss the role of thrombolysis in anticoagulated patients with acute ischemic stroke and factors to consider concerning restarting anticoagulation after acute ischemic and hemorrhagic stroke.

Source: International Journal of Stroke

DOI: 10.1111/ijs.12295

Authors: Graeme J. Hankey, Bo Norrving, Werner Hacke, Thorsten Steiner

Institutions: The University of Western Australia, Lund University, Heidelberg University, Klinikum Frankfurt Höchst

Language: English

Topic: Atrial Fibrillation Management and Outcomes

Subfield: Cardiology and Cardiovascular Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funders: Johns Hopkins University, Janssen Scientific Affairs